Prof. Dr. Mutlu DemirayMedical Oncology
The work of Prof. Dr. Mutlu Demiray and his team on the RAF-1 protein was published by ASCO. The team, which cleared a tumour in three months with MEK treatment, also describes personalized cancer vaccines and tracking tumours in the blood.
Read More
Turkey — one of the first three countries able to treat cancer without chemotherapy using smart drugs developed from gene maps — drew patients from over 70 countries in 2022. Prof. Dr. Mutlu Demiray on the importance of personalized treatment.
Read More
Given HIV-infected blood during cancer treatment in Dagestan, Magomed Saidakhedov was told in Moscow 'there is nothing to be done.' In Turkey, treatment guided by his tumour's genetic map cleared the tumour completely.
Read More
On Lung Cancer Awareness Day, Prof. Dr. Mutlu Demiray explains that lung cancer rates are falling thanks to tobacco policies: "Smoking is like playing Russian roulette."
Read More
Next-generation sequencing (NGS) now identifies a tumour’s molecular features in a fraction of the time. Prof. Dr. Mutlu Demiray describes the shift to organ-agnostic, personalized therapy: “Instead of searching for a needle with a flashlight, we turned the lights on.”
Read More
An interview with Prof. Dr. Mutlu Demiray on the shift from organ-based to molecular, personalized treatment, the rise of immunotherapy and Turkey's bioinformatics infrastructure.
Read More
Technopol Istanbul Director General Orhan Çömlek and Prof. Dr. Mutlu Demiray call for regulatory change to end foreign dependency in the pharmaceutical industry, citing domestic production and the vitamin C example.
Read More
South African teacher Judith Çubukçu, who beat breast cancer, recounts her diagnosis and treatment; surgeon Op. Dr. Sevim Kuşlu Çiçek and oncologist Assoc. Prof. Dr. Mutlu Demiray reflect on the process.
Read More